Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.69 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 4/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054693 | 1.00 | CACNA2D1 (0.69) | CACNA2D1CACNA1CCACNB3PGRADRA1A | |
| SCHEMBL17278430 | 1.00 | CACNA2D1 (0.69) | CACNA2D1CACNA1CCACNB3PGRADRA1A | |
| SCHEMBL18100236 | 0.85 | ALDH1A1 (0.60) | CACNA2D1CACNA1CCACNB3PGRADRA1A | |
| SCHEMBL13382791 | 0.85 | ALDH1A1 (0.60) | CACNA2D1CACNA1CCACNB3PGRADRA1A | |
| SCHEMBL12081863 | 0.83 | — | — | |
| Pregabalin SCHEMBL15497 | 0.82 | CACNA2D1 (1.00) | CACNA2D1CACNA1CCACNB3PGRADRA1A | |
| Pregabalin SCHEMBL1561104 | 0.82 | CACNA2D1 (1.00) | CACNA2D1CACNA1CCACNB3PGRADRA1A | |
| Pregabalin SCHEMBL263450 | 0.82 | CACNA2D1 (1.00) | CACNA2D1CACNA1CCACNB3PGRADRA1A | |
| Pregabalin SCHEMBL2370227 | 0.82 | CACNA2D1 (1.00) | CACNA2D1CACNA1CCACNB3PGRADRA1A | |
| SCHEMBL2693051 | 0.82 | CACNA2D1 (0.69) | CACNA2D1CACNA1CCACNB3PGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-3265074-B1 | PREGABALIN IMMUNOASSAYS | ARK DIAGNOSTICS INC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-9958464-B2 | Pregabalin immunoassays | ARK DIAGNOSTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2017-08-24 | — | — | US | disclosed |
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160282370-A1 | PREGABALIN IMMUNOASSAYS | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2016-09-29 | — | — | US | disclosed |
| US-9320725-B2 | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid | GRUENENTHAL GMBH (DE) | 2016-04-26 | — | — | US | disclosed |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-11-26 | — | — | US | disclosed |
| US-8168828-B2 | Process for the preparation of pregabalin | MSN LABORATORIES, LIMITED (IN) | 2012-05-01 | — | — | US | disclosed |
| US-20120041212-A1 | PROCESS FOR THE PREPARATION OF PREGABALIN | DIVI'S LABORATORIES LIMITED (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20110190393-A1 | NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS (UK) LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20100324139-A1 | PROCESS TO PREGABALIN | GENERICS [UK] LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7763749-B2 | Method for the preparation of Pregabalin and salts thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-07-27 | — | — | US | disclosed |
| US-20100179345-A1 | NOVEL PROCESS FOR THE PREPARATION OF PREGABALIN | MSN LABORATORIES, LIMITED (IN) | 2010-07-15 | — | — | US | disclosed |
| WO-2009118580-A2 | GABA ANALOGS, COMPOSITIONS, AND METHODS FOR MANUFACTURING THEREOF | ANCHEN LABORATORIES, INC (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20080311635-A1 | PROCESS FOR THE PREPARATION OF (S)(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | DIPHARMA FRANCIS S.R.L. (IT) | 2008-12-18 | — | — | US | disclosed |
| US-7462737-B2 | Pregabalin free of isobutylglutaric acid and a process for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-09 | — | — | US | disclosed |
| US-20070073085-A1 | Method for the preparation of pregabalin and salts thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | CACNA2D1 4820/4885CACNA1C 4813/4885CACNB3 4619/4885 |
| US-20080311635-A1 | PROCESS FOR THE PREPARATION OF (S)(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | ADH5, ALDH7A1, ADH1C | CACNA2D1 360/4885CACNA1C 351/4885CACNB3 575/4885 |
| US-20120041212-A1 | PROCESS FOR THE PREPARATION OF PREGABALIN | GABRA5, GABRA6, GABRE | CACNA2D1 175/4885CACNA1C 206/4885CACNB3 252/4885 |
| US-20160282370-A1 | PREGABALIN IMMUNOASSAYS | GABRG3, GABRG1, GABRB2 | CACNA2D1 107/4885CACNA1C 168/4885CACNB3 46/4885 |
| US-20110190393-A1 | NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GLUL, GRIK5, GABRE | CACNA2D1 244/4885CACNA1C 98/4885CACNB3 114/4885 |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | CACNA2D1 4227/4885CACNA1C 3005/4885CACNB3 2185/4885 |
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | CACNA2D1 4820/4885CACNA1C 4813/4885CACNB3 4619/4885 |
| US-20070073085-A1 | Method for the preparation of pregabalin and salts thereof | GABRG1, GABRG2, GABRG3 | CACNA2D1 127/4885CACNA1C 26/4885CACNB3 32/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | CACNA2D1 4464/4885CACNA1C 3394/4885CACNB3 2558/4885 |
| US-20100324139-A1 | PROCESS TO PREGABALIN | GABRB2, GABRE, GABRB1 | CACNA2D1 195/4885CACNA1C 66/4885CACNB3 75/4885 |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | CACNA2D1 4227/4885CACNA1C 3005/4885CACNB3 2185/4885 |
| US-20100179345-A1 | NOVEL PROCESS FOR THE PREPARATION OF PREGABALIN | GAP43, RIMKLA, GABRE | CACNA2D1 504/4885CACNA1C 246/4885CACNB3 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.